Core Viewpoint - Shenzhen Beixin Life Technology Co., Ltd. (Beixin Life) is set to undergo its IPO review on July 18, marking it as the second pharmaceutical company to utilize the fifth set of standards for listing on the Sci-Tech Innovation Board [1][3] Group 1: Company Overview - Beixin Life focuses on the research, development, production, and sales of innovative medical devices for precise diagnosis and treatment of cardiovascular diseases [3] - The company is recognized as a national high-tech enterprise and aims to provide transformative solutions for cardiovascular disease treatment [3] Group 2: IPO Progress - Beixin Life's IPO journey began with acceptance on March 30, 2023, followed by an inquiry phase starting on April 24, 2023 [3] - The IPO process faced a halt due to tightened review standards but resumed after the China Securities Regulatory Commission announced the restart of the fifth set of standards [3][10] - The company disclosed its second round of inquiry responses on July 8, 2023, and received the opportunity for the IPO review on July 11, 2023 [3] Group 3: Financial Performance - Beixin Life reported continuous net losses during the reporting period, with revenues of approximately 92.45 million yuan, 184 million yuan, and 317 million yuan for the years 2022, 2023, and 2024 respectively [3] - Corresponding net losses were approximately -290 million yuan, -140 million yuan, and -43.6 million yuan, showing a trend of reduced losses year over year [3] Group 4: Market Context - There are currently five pharmaceutical companies, including Beixin Life, queuing for IPOs under the fifth set of standards on the Sci-Tech Innovation Board [5] - He Yuan Bio is noted as the first company to pass the review under the restarted fifth set of standards, with others like Si Zhe Rui and Bi Bei Te also in the registration phase [6][10] - The fifth set of standards aims to support innovative pharmaceutical companies that are not yet profitable but possess core technologies and market potential [10]

Group 1 - The core point of the news is the reintroduction of the fifth listing standard for the Sci-Tech Innovation Board, allowing companies with no profits or revenue to go public, particularly benefiting special industries [1][3][4] - The fifth listing standard requires a minimum market value of 4 billion yuan, and companies must have significant market potential and approved core products for certain industries, such as biomedicine [4][5] - The new regulations expand the eligible industries for the fifth standard to include artificial intelligence, commercial aerospace, and low-altitude economy, aiming to accelerate the establishment of typical cases [9][10] Group 2 - The introduction of a system for qualified professional institutional investors is part of the new regulations, which will help assess the reliability of companies applying under the fifth standard [10][11][17] - A pre-review mechanism has been established to protect sensitive information for technology companies, allowing them to apply for confidentiality during the listing process [18][19][20] - The establishment of a Sci-Tech Growth Layer is part of the new regulations, with specific criteria for companies to enter this layer, indicated by a "U" in their stock abbreviation [23][25][29]

Core Viewpoint - The resumption of the fifth set of standards for the Sci-Tech Innovation Board (STAR Market) is expected to revitalize the biopharmaceutical industry, which has faced a capital winter over the past two years, providing new investment opportunities and hope for long-term, capital-intensive projects [3][4][5]. Group 1: Industry Overview - The approval of Wuhan Heyuan Biotechnology Co., Ltd. (Heyuan Bio) marks the first company to pass under the restarted fifth set of standards, indicating significant market expectations and a renewed focus on the biopharmaceutical sector [3][5]. - The biopharmaceutical industry is characterized by long cycles and substantial capital requirements, making stable policy support crucial for its growth [7][8]. Group 2: Investment Insights - Investors are concerned about whether the approval standards have been raised, with expectations that companies may need to provide more robust clinical data, potentially requiring phase III clinical trials for approval [8][9]. - The commercial viability and profitability of biopharmaceutical companies will be critical under the new standards, with a focus on meeting unmet clinical needs and maintaining competitive positioning in the market [10][9]. Group 3: Company Case Study - Heyuan Bio's core product, HY1001, has completed phase III clinical trials and is projected to launch in 2025, with expectations of significant sales starting in 2026 and profitability by 2027 [9][10]. - The company has established a sales network across over 30 provinces in China through agreements with major distributors, enhancing its market presence [9]. Group 4: Market Trends - The successful listing of Heyuan Bio may lead to a resurgence of interest in Pre-IPO and mid-stage biopharmaceutical investments, which had previously stagnated due to market conditions [15][16]. - The current market environment is seeing a shift towards more rational investment behavior, with investors becoming more cautious after previous market downturns, yet maintaining a long-term optimistic outlook for the industry [17][18].

Core Viewpoint - He Yuan Bio is the first company to be reviewed under the newly established fifth set of standards for the Sci-Tech Innovation Board, following the announcement of the growth tier for unprofitable companies [2][4]. Company Overview - He Yuan Bio, established in 2006, focuses on the research and development of innovative drugs, with its core product HY1001 (recombinant human albumin injection) having completed Phase III clinical trials and included in the priority review process by the National Medical Products Administration [4][5]. - The company has not yet generated revenue from its core innovative drug products, with current income primarily from pharmaceutical excipients and research reagents [5]. Financial and Operational Insights - He Yuan Bio has invested a total of 386 million yuan in R&D from 2022 to 2024, with a workforce of 178 employees, of which 122 are dedicated to R&D, accounting for nearly 70% [5]. - The innovative drug industry typically requires significant R&D investment and long development cycles, which contributes to He Yuan Bio's current lack of profitability [5]. Product Development and Market Position - The core product HY1001 aims to supplement or enhance the levels of human serum albumin in the blood, potentially replacing plasma-derived human serum albumin, which is currently widely used in clinical settings but largely imported [6]. - He Yuan Bio has achieved breakthroughs in increasing the expression levels and purity of recombinant human albumin, reducing production costs and enhancing clinical safety, with related technology awarded the National Technology Invention Award (Second Class) [6]. Industry Context - As of 2024, the 20 companies listed under the fifth set of standards on the Sci-Tech Innovation Board collectively generated over 14 billion yuan in revenue, a growth of over 40% compared to 2023 [8]. - The first quarter of 2025 saw these companies achieve a combined revenue of 3.78 billion yuan, reflecting a year-on-year growth of 29.27% [8]. - The fifth set of standards has supported the listing of high-quality tech companies that have not yet formed significant revenue scales, demonstrating the adaptability and inclusiveness of the Sci-Tech Innovation Board [9].

Core Viewpoint - The article discusses the upcoming IPO application review for He Yuan Bio, marking the restart of the fifth listing standard on the Sci-Tech Innovation Board, which has been expanded to include various industries beyond pharmaceuticals [1][2][7]. Group 1: Company Overview - He Yuan Bio is an innovative biopharmaceutical company focused on original innovation, having developed a leading rice recombinant protein expression system with a yield of 20-30g/kg of rice protein [3][4]. - The company has established two major technology platforms and has eight drug candidates in its pipeline, with six currently in clinical research [3]. Group 2: Financial Performance - He Yuan Bio has reported continuous losses over the past three years, with losses of 150 million RMB in 2024, 187 million RMB in 2023, and 144 million RMB in 2022 [4]. Group 3: IPO Plans - The company plans to raise 2.4 billion RMB through its IPO, which will be allocated to the construction of a recombinant human albumin industrialization base, new drug research and development, and to supplement working capital [5]. Group 4: Regulatory Context - The fifth listing standard on the Sci-Tech Innovation Board is designed for companies with complex product technologies and long R&D cycles, and it has been successfully implemented in the biopharmaceutical sector [6][7]. - The recent reforms aim to enhance the inclusivity and adaptability of the listing standards, particularly for high-quality, unprofitable tech companies [6].

Core Viewpoint - The establishment of a growth tier in the Sci-Tech Innovation Board (STAR Market) and the resumption of the listing of unprofitable companies under the fifth set of standards is a significant move to support innovative technology enterprises, exemplified by He Yuan Bio's upcoming listing as the first company under these new standards [2][4]. Group 1: Company Overview - He Yuan Bio is primarily engaged in the research and development of innovative drugs, with its core product HY1001 (recombinant human albumin injection) being a class 1 new drug that has completed phase III clinical trials and is under priority review by the National Medical Products Administration [2]. - Since its establishment, He Yuan Bio has invested a total of 386 million yuan in R&D from 2022 to 2024, with 122 out of 178 employees dedicated to research, accounting for nearly 70% of the workforce [2]. Group 2: Financial Performance and Market Trends - In 2024, 20 companies listed under the fifth set of standards on the STAR Market achieved a combined revenue exceeding 14 billion yuan, representing a growth of over 40% compared to 2023, with 16 companies generating over 1 billion yuan in revenue [3]. - The average R&D investment for these 20 companies in 2024 was 500 million yuan, surpassing the A-share average of 364 million yuan [4]. - As of June 2023, 19 out of the 20 companies have launched core products, and a total of 17 class 1 new drugs have been introduced to the market since 2018, accounting for approximately 12% of the total approved domestic innovative drugs during the same period [4].

Core Viewpoint - The recent launch of the "1+6" new policy for the Sci-Tech Innovation Board (STAR Market) by the China Securities Regulatory Commission (CSRC) has garnered significant market attention, particularly the reintroduction and expansion of the fifth listing standard, which opens up opportunities for high-quality unprofitable companies to go public [1][3][4] Group 1: Policy Changes and Implications - The fifth listing standard has been expanded to cover cutting-edge fields such as artificial intelligence, commercial aerospace, and low-altitude economy, enhancing the inclusivity and adaptability of the capital market for hard-tech companies [3][4] - The introduction of a new "U" label for unprofitable companies in the newly established Sci-Tech Growth Layer aims to improve transparency and help investors better identify and assess risks associated with these companies [9][10] - The new policy encourages collaboration between companies and experienced institutional investors, which is expected to enhance the identification and support of high-quality unprofitable enterprises [5][6] Group 2: Market Dynamics and Investor Considerations - The involvement of seasoned institutional investors is designed to provide a more accurate assessment of companies' innovation potential beyond just financial metrics, thereby guiding capital towards promising unprofitable firms [5][6] - The policy may lead to a situation where companies seek to partner with institutional investors primarily to meet listing requirements, potentially resulting in superficial collaborations rather than genuine partnerships [7][8] - The establishment of differentiated exit standards for companies in the Sci-Tech Growth Layer aims to ensure that only those with sustainable growth and profitability can transition out, thereby enhancing market quality [11][12] Group 3: IPO Pre-Review Mechanism - The newly introduced IPO pre-review mechanism allows companies to identify and address potential issues before formal submission, which could shorten the review cycle and increase the likelihood of successful listings [14][15] - This mechanism is particularly suited for strategic emerging industries with clear core technology projects that have significant implications for national and industry development [15] - However, the pre-review process may not fully uncover all issues, and there are concerns about the lack of transparency and potential information asymmetry in the market [16][17][18]

21世纪经济报道记者 韩利明 上海报道 6月18日，"证监会发布"官微显示，中国证监会主席吴清在2025陆家嘴论坛上宣布，将更好发挥科创 板"试验田"作用，加力推出进一步深化改革的"1+6"政策措施，统筹推进投融资综合改革和投资者权益 保护，加快构建更有利于支持全面创新的资本市场生态。 其中，"1"指在科创板设置科创成长层，并且重启未盈利企业适用科创板第五套标准上市，更加精准服 务技术有较大突破、商业前景广阔、持续研发投入大的优质科技企业，同时在强化信息披露和风险揭 示、加强投资者适当性管理等方面做出专门安排。 "6"涵盖试点引入资深专业投资者制度，扩大第五套标准适用范围，支持在审未盈利科技企业面向老股 东开展增资扩股等活动，完善科创板公司再融资制度和战略投资者认定标准等6项改革措施。 对此，资深投行人士王骥跃向21世纪经济报道分析，"资本市场是落实国家战略支持实体经济的工具， 监管层的重要表述是在落实中央政策要求，释放出对科创企业的重磅支持信号，其核心在于通过扶持优 质企业、助力产业链发展，实现提升上市公司质量的首要目标。在此目标导向下，法规设定的各类条件 需遵循'若无法满足目标则应修订法规'的基本原则。" ...

未盈利企业上市，历来是市场关注的焦点。 在6月18日召开的2025陆家嘴论坛上，中国证监会主席吴清表示，将聚焦提升制度的包容性和适应性， 以深化科创板、创业板改革为抓手，更好发挥科创板"试验田"作用，加力推出进一步深化改革 的"1+6"政策措施，统筹推进投融资综合改革和投资者权益保护，加快构建更有利于支持全面创新的资 本市场生态。 21世纪经济报道记者 崔文静 张赛男 实习生张长荣 北京、上海报道 吴清提出的"1+6"政策，意味着什么？系列政策利好背后，哪些企业将更多受益？将对资本市场带来哪 些影响？ 一、重启未盈利企业适用科创板第五套标准上市，意味着什么？ 科创板创立之初，率先确立多元包容的上市标准，打破A股对企业盈利门槛的刚性约束，中芯国际、百 利天恒等新质生产力领域的行业领军企业得以在境内上市。第五套上市标准开创境内资本市场允许无收 入、未盈利企业上市先河，仅对市值、主要业务或产品的研发进展、市场空间等提出要求，为艾力斯、 神州细胞等一批具备核心研发实力、亟需突破资金瓶颈的创新药企业提供融资支持。 具体来看"1+6"政策措施，"1"是在科创板设置科创成长层，并且重启未盈利企业适用于科创板第五套标 准上市 ...

支持优质未盈利科技企业发行上市、稳妥恢复科创板第五套标准适用……资本市场在支持科技创新和新质生产力发展方面持续加码，释放出推动优质"硬 科技"企业在A股上市的积极信号。 一位券商投行人士指出，稳妥恢复科创板第五套标准适用，能够推动更多未盈利优质科创企业解决融资难题，加速创新成果转化，当前要尽快推出具有示范 意义的典型案例，需要健全精准识别科技企业的制度机制，完善科技企业信息披露规则，引导市场客观冷静地对待科技企业成长中的风险，营造包容创新的 市场生态。 第五套标准含金量几何 科创板第五套标准是科创板设立之初推出的上市标准之一，以"市值+研发"作为评估方式，不对企业营收和净利润规模作出要求，而是强调"主要业务或产品 需经国家有关部门批准，市场空间大""已取得阶段性成果"等，为暂不具备盈利能力但真正有核心竞争力的企业登陆资本市场提供便利，意在支持未盈利的、 具有高成长潜力的科技企业。 田利辉认为，这次恢复科创板第五套标准适用不会"大水漫灌"，骤然提升股票供给，而是要精准滴灌，优中选优。从"利润门槛"转向"技术含金量+商业化前 景"双维度评估，实现筛选机制升级。会将未盈利企业的估值定价权交给市场，实现风险定价权转移 ...